Eli Lilly and Company (LLY) — Stock Price, Chart & Analysis
Eli Lilly and Company (LLY) is a Healthcare stock currently trading at $1,185.71, down 0.52% on the day. It carries a market capitalization of $1.06T and a trailing P/E ratio of 40.00. Over the past 52 weeks, LLY has traded between $625.90 and $1249.45. Eli Lilly and Company pays a dividend yielding 0.6%. View the live LLY chart, technical opinion, analyst ratings, fundamentals and latest news below.
Eli Lilly and Company (LLY) key data
| Price | $1,185.71 |
| Change (today) | -0.52% |
| Previous close | $1,191.94 |
| Market cap | $1.06T |
| P/E ratio (TTM) | 40.00 |
| EPS (TTM) | $29.64 |
| Dividend yield | 0.6% |
| 52-week high | $1249.45 |
| 52-week low | $625.90 |
| Beta | 0.51 |
| Avg. volume | 3.05M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about Eli Lilly and Company (LLY)
How much does one share of Eli Lilly and Company cost?
As of the latest update, one share of Eli Lilly and Company (LLY) trades at $1,185.71 (-0.52% today).
What is Eli Lilly and Company's market cap?
Eli Lilly and Company has a market capitalization of approximately $1.06T.
What is Eli Lilly and Company's P/E ratio?
Eli Lilly and Company has a trailing price-to-earnings (P/E) ratio of 40.00.
What is Eli Lilly and Company's earnings per share (EPS)?
Eli Lilly and Company's trailing twelve-month EPS is $29.64.
Does Eli Lilly and Company pay a dividend?
Yes — Eli Lilly and Company pays a dividend with a yield of 0.6% ($6.92 per share annually).
What is Eli Lilly and Company's 52-week trading range?
Over the past year, LLY has traded between $625.90 and $1249.45.
What is the analyst price target for Eli Lilly and Company?
The mean analyst price target for Eli Lilly and Company is $1297.31. This is informational only and not investment advice.
Latest Eli Lilly and Company (LLY) news
- Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a ProblemNews · Aug 7, 2026
- Novo Nordisk Stock Rises After GLP-1 Antitrust WinNews · Aug 7, 2026
- Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's ZepboundNews · Aug 7, 2026
- The Two Divergent Paths Priced Into Eli Lilly StockNews · Aug 7, 2026
- Stock Market Rally Powers Ahead; SpaceX, Palantir, Sandisk Are Key Earnings Movers: Weekly ReviewNews · Aug 7, 2026
- Lilly and Novo Win a Key GLP-1 Antitrust FightNews · Aug 7, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live LLY dashboard…